Frederick S Vizeacoumar
Overview
Explore the profile of Frederick S Vizeacoumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gahramanov V, Vizeacoumar F, Morales A, Bonham K, Sakharkar M, Kumar S, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769257
Loss of function screens using shRNA (short hairpin RNA) and CRISPR (clustered regularly interspaced short palindromic repeats) are routinely used to identify genes that modulate responses of tumor cells to...
2.
Ding Y, Denomy C, Freywald A, Pan Y, Vizeacoumar F, Vizeacoumar F, et al.
Cells
. 2024 Oct;
13(19.
PMID: 39404416
Generally, essential genes identified using shRNA and CRISPR are not always the same, raising questions about the choice between these two screening platforms. To address this, we systematically compared the...
3.
Kumar P, Smith D, Key J, Dong H, Ganapathysamy A, Maranda V, et al.
Gynecol Oncol
. 2024 Jul;
188:162-168.
PMID: 38970843
Objective: Dedifferentiated endometrial carcinoma (DDEC) characterized by SWItch/Sucrose Non-Fermentable (SWI/SNF) complex inactivation is a highly aggressive type of endometrial cancer without effective systemic therapy options. Its uncommon nature and aggressive...
4.
Dolgova N, Uhlemann E, Boniecki M, Vizeacoumar F, Ara A, Nouri P, et al.
Elife
. 2024 Apr;
13.
PMID: 38640016
Mediator of ERBB2-driven cell motility 1 (MEMO1) is an evolutionary conserved protein implicated in many biological processes; however, its primary molecular function remains unknown. Importantly, MEMO1 is overexpressed in many...
5.
Salapa H, Thibault P, Libner C, Ding Y, Clarke J, Denomy C, et al.
Nat Commun
. 2024 Jan;
15(1):356.
PMID: 38191621
Neurodegeneration is the primary driver of disease progression in multiple sclerosis (MS) resulting in permanent disability, creating an urgent need to discover its underlying mechanisms. Herein, we establish that dysfunction...
6.
Kobel M, Yang R, Kang E, Al-Shamma Z, Cook L, Kinloch M, et al.
Gynecol Oncol
. 2023 Oct;
178:80-88.
PMID: 37820398
Objective: Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A common MAPK pathway alteration...
7.
Hanover G, Vizeacoumar F, Banerjee S, Nair R, Dahiya R, Osornio-Hernandez A, et al.
Cell Rep
. 2023 Jul;
42(7):112670.
PMID: 37392382
Eph receptors and their ephrin ligands are viewed as promising targets for cancer treatment; however, targeting them is hindered by their context-dependent functionalities. To circumvent this, we explore molecular landscapes...
8.
El Zawily A, Vizeacoumar F, Dahiya R, Banerjee S, Bhanumathy K, Elhasasna H, et al.
Clin Cancer Res
. 2023 Mar;
29(14):2686-2701.
PMID: 36976175
Purpose: Accumulating analyses of pro-oncogenic molecular mechanisms triggered a rapid development of targeted cancer therapies. Although many of these treatments produce impressive initial responses, eventual resistance onset is practically unavoidable....
9.
Arna A, Patel H, Singh R, Vizeacoumar F, Kusalik A, Freywald A, et al.
Front Oncol
. 2023 Feb;
12:1087989.
PMID: 36761420
DEAD/H-box helicases are implicated in virtually every aspect of RNA metabolism, including transcription, pre-mRNA splicing, ribosomes biogenesis, nuclear export, translation initiation, RNA degradation, and mRNA editing. Most of these helicases...
10.
Maranda V, Zhang Y, Vizeacoumar F, Freywald A, Vizeacoumar F
Methods Mol Biol
. 2022 Dec;
2614:397-409.
PMID: 36587138
Large-scale genetic screens are becoming increasingly used as powerful tools to query the genome to identify therapeutic targets in cancer. The advent of the CRISPR technology has revolutionized the effectiveness...